St. John's Wort components and the brain: Uptake, concentrations reached and the mechanisms underlying pharmacological effects

Current Drug Metabolism

Volumn 10, Issue 9, 2009, Pages 1055-1065

  Caccia, Silvio ^a   Gobbi, Marco ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Acylphloroglucinols; Brain to blood distribution; Flavonoids; Naphthodianthrones; Neurochemical effects; Pharmacokinetics

Indexed keywords

AMENTOFLAVONE; APIGENIN; BIAPIGENIN; CYCLOPSEUDOHYPERICIN; HYPERFORIN; HYPERFORIN DICYCLOHEXYLAMMONIUM; HYPERFORIN SODIUM; HYPERFORIN TRIMETHOXYBENZOATE; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; ISORHAMNETIN; NEUROTRANSMITTER RECEPTOR; POLYPHENOL; PROTOHYPERICIN; PROTOPSEUDOHYPERICIN; PSEUDOHYPERICIN; QUERCETIN; UNCLASSIFIED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY DISORDER; BLOOD BRAIN BARRIER; DOSE RESPONSE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG SOLUBILITY; HUMAN; MOLECULAR WEIGHT; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; REVIEW;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; BLOOD-BRAIN BARRIER; BRAIN; FLAVONOLS; HUMANS; HYPERICUM; NOOTROPIC AGENTS; PERMEABILITY; PERYLENE; PHLOROGLUCINOL; PLANT PREPARATIONS; PSYCHOTROPIC DRUGS; TERPENES;

EID: 76749150603     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790711878     Document Type: Review

References (129)

1. Linde, K.; Berner, M.M.; Kriston, L. St John's wort for major depression. Cochrane Database Syst. Rev., 2008, 4, CD000448.
2. Greeson, J.M.; Sanford, B.; Monti, D.A. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl), 2001, 153(4), 402-414.
3. Rodriguez-Landa, J.F.; Contreras, C.M. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine, 2003, 10(8), 688-699.
4. Muller, W.E. Current St John's wort research from mode of action to clinical efficacy. Pharmacol. Res., 2003, 47(2), 101-109.
5. Mennini, T.; Gobbi, M. The antidepressant mechanism of Hypericum perforatum. Life Sci., 2004, 75(9), 1021-1027.
6. Kumar, V. Potential medicinal plants for CNS disorders: an overview. Phytother. Res., 2006, 20(12), 1023-1035.
7. Zhang, Z.J. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci., 2004, 75(14), 1659-1699.
8. Uzbay, T.I. Hypericum perforatum and substance dependence: a review. Phytother. Res., 2008, 22(5), 578-582.
9. Trofimiuk, E.; Braszko, J.J. Alleviation by Hypericum perforatum of the stress-induced impairment of spatial working memory in rats. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 376(6), 463-471.
10. Klusa, V.; Germane, S.; Noldner, M.; Chatterjee, S.S. Hypericum extract and hyperforin: memory-enhancing properties in rodents. Pharmacopsychiatry, 2001, 34 (Suppl 1) (S61-69).
11. Khalifa, A.E. Hypericum perforatum as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. J. Ethnopharmacol., 2001, 76(1), 49-57.
12. Widy-Tyszkiewicz, E.; Piechal, A.; Joniec, I.; Blecharz-Klin, K. Long term administration of Hypericum perforatum improves spatial learning and memory in the water maze. Biol. Pharm. Bull., 2002, 25(10), 1289-1294.
13. Dinamarca, M.C.; Cerpa, W.; Garrido, J.; Hancke, J.L.; Inestrosa, N.C. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Mol. Psychiatry, 2006, 11(11), 1032-1048.
14. Dinamarca, M.C.; Arrazola, M.; Toledo, E.; Cerpa, W.F.; Hancke, J.; Inestrosa, N.C. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem. Biol. Interact., 2008, 175(1-3), 142-149.
15. Lu, Y.H.; Du, C.B.; Liu, J.W.; Hong, W.; Wei, D.Z. Neuroprotective effects of Hypericum perforatum on trauma induced by hydrogen peroxide in PC12 cells. Am. J. Chin. Med., 2004, 32(3), 397-405.
16. Breyer, A.; Elstner, M.; Gillessen, T.; Weiser, D.; Elstner, E. Glutamate-induced cell death in neuronal HT22 cells is attenuated by extracts from St. John's wort (Hypericum perforatum L.). Phytomedicine, 2007, 14(4), 250-255.
17. Silva, B.; Oliveira, P.J.; Dias, A.; Malva, J.O. Quercetin, kaempferol and biapigenin from Hypericum perforatum are neuroprotective against excitotoxic insults. Neurotox Res., 2008, 13(3-4), 265-279.
18. Silva, B.A.; Dias, A.C.; Ferreres, F.; Malva, J.O.; Oliveira, C.R. Neuroprotective effect of H. perforatum extracts on beta-amyloid-induced neurotoxicity. Neurotox. Res., 2004, 6(2), 119-130.
19. Butterweck, V. Mechanism of action of St John's wort in depression : what is known? CNS Drugs, 2003, 17(8), 539-562.
20. Butterweck, V.; Schmidt, M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr., 2007, 157(13-14), 356-361.
21. Buchholzer, M.L.; Dvorak, C.; Chatterjee, S.S.; Klein, J. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J. Pharmacol. Exp. Ther., 2002, 301(2), 714-719.
22. Leuner, K.; Kazanski, V.; Muller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Muller, W.E. Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J., 2007, 21(14), 4101-4111.
23. Zhou, J.; Du, W.; Zhou, K.; Tai, Y.; Yao, H.; Jia, Y.; Ding, Y.; Wang, Y. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat. Neurosci., 2008, 11(7), 741-743.
24. Nahrstedt, A.; Butterweck, V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry, 1997, 30 (Suppl 2),129-134.
25. Jurgenliemk, G.; Nahrstedt, A. Phenolic compounds from Hypericum perforatum. Planta Med., 2002, 68(1), 88-91.
26. Jensen, A.G.; Hansen, S.H.; Nielsen, E.O. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci., 2001, 68(14), 1593-1605.
27. Caccia, S. Antidepressant-like components of Hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Curr. Drug Metab., 2005, 6(6), 531-543.
28. Caccia, S. Main components of St. John's Wort (Hypericum perforatum) extracts: an overview of their pharmacokinetics and metabolism. Curr. Pharm. Anal., 2006, 2(25-30.
29. Tatsis, E.C.; Boeren, S.; Exarchou, V.;Troganis, A.N.; Vervoort, J.; Gerothanassis, I.P. Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. Phytochemistry, 2007, 68(3), 383-393.
30. Chatterjee, S.S.; Bhattacharya, S.K.; Wonnemann, M.; Singer, A.; Muller, W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci., 1998, 63(6), 499-510.
31. Chatterjee, S.S.; Noldner, M.; Koch, E.; Erdelmeier, C.Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry, 1998, 31 (Suppl 1), 7-15.
32. Gambarana, C.; Tolu, P.L.; Masi, F.; Rinaldi, M.; Giachetti, D.; Morazzoni, P.; De Montis, M.G. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry, 2001, 34 (Suppl 1), S42-44.
33. Cervo, L.; Rozio, M.; Ekalle-Soppo, C.B.; Guiso, G.; Morazzoni, P.; Caccia, S. Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts. Psychopharmacology (Berl), 2002, 164(4), 423-428.
34. Cervo, L.; Mennini, T.; Rozio, M.; Ekalle-Soppo, C.B.; Canetta, A.; Burbassi, S.; Guiso, G.; Pirona, L.; Riva, A.; Morazzoni, P.; Caccia, S.; Gobbi, M. Potential antidepressant properties of IDN 5491 (hyperforin- trimethoxybenzoate), a semisynthetic ester of hyperforin. Eur. Neuropsychopharmacol., 2005, 15(2), 211-218.
35. Butterweck, V.; Christoffel, V.; Nahrstedt, A.; Petereit, F.; Spengler, B.; Winterhoff, H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models. Life Sci., 2003, 73(5), 627-639.
36. Gambarana, C.; Grappi, S.; Nanni, G. Dose dependent antidepressant activity of Hyperforin in rats. Soc. Neurosci. Abs., 2001, 27(975.912).
37. Zanoli, P.; Rivasi, M.; Baraldi, C.; Baraldi, M. Pharmacological activity of hyperforin acetate in rats. Behav. Pharmacol., 2002, 13(8), 645-651.
38. Grundmann, O.; Kelber, O.; Butterweck, V. Effects of St. John's wort extract and single constituents on stress-induced hyperthermia in mice. Planta Med., 2006, 72(15), 1366-1371.
39. Vandenbogaerde, A.; Zanoli, P.; Puia, G.; Truzzi, C.; Kamuhabwa, A.; De Witte, P.; Merlevede, W.; Baraldi, M. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacol. Biochem. Behav., 2000, 65(4), 627-633.
40. Beerhues, L. Hyperforin. Phytochemistry, 2006, 67(20), 2201-2207.
41. Medina, M.A.; Martinez-Poveda, B.; Amores-Sanchez, M.I.; Quesada, A.R. Hyperforin: more than an antidepressant bioactive compound? Life Sci., 2006, 79(2), 105-111.
42. Mai, I.; Bauer, S.; Perloff, E.S.; Johne, A.; Uehleke, B.; Frank, B.; Budde, K.; Roots, I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin. Pharmacol. Ther., 2004, 76(4), 330-340.
43. Mueller, S.C.; Majcher-Peszynska, J.; Uehleke, B.; Klammt, S.; Mundkowski, R.G.; Miekisch, W.; Sievers, H.; Bauer, S.; Frank, B.; Kundt, G.; Drewelow, B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol., 2006, 62(1), 29-36.
44. Zhou, S.; Lim, L.Y.; Chowbay, B. Herbal modulation of P-glycoprotein. Drug Metab. Rev., 2004, 36(1), 57-104.
45. Ott, M; Fricker, G; Bauer, B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J. Pharmacol. Exp. Ther., 2009, 329 (1),141-9.
46. Krusekopf, S.; Roots, I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharmacogenet. Genomics, 2005, 15(11), 817-829.
47. Keller, J.H.; Karas, M.; Muller, W.E.; Volmer, D.A.; Eckert, G.P.; Tawab, M.A.; Blume, H.H.; Dingermann, T.; Schubert-Zsilavecz, M. Determination of hyperforin in mouse brain by highperformance liquid chromatography/tandem mass spectrometry. Anal. Chem., 2003, 75(22), 6084-6088.
48. Weber, C.C.; Kressmann, S.; Fricker, G.; Muller, W.E. Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry, 2004, 37(6), 292-298.
49. Perloff, M.D.; von Moltke, L.L.; Stormer, E.; Shader, R.I.; Green-blatt, D.J. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol., 2001, 134(8), 1601-1608.
50. Gutmann, H.; Poller, B.; Buter, K.B.; Pfrunder, A.; Schaffner, W.; Drewe, J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med., 2006, 72(8), 685-690.
51. Biber, A.; Fischer, H.; Romer, A.; Chatterjee, S.S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry, 1998, 31 (Suppl 1), 36-43.
52. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung, 2005, 55(10), 561-568.
53. Johne, A.; Schmider, J.; Brockmoller, J.; Stadelmann, A.M.; Stormer, E.; Bauer, S.; Scholler, G.; Langheinrich, M.; Roots, I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum. J. Clin. Psychopharmacol., 2002, 22(1), 46-54.
54. Cantoni, L.; Rozio, M.; Mangolini, A.; Hauri, L.; Caccia, S. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol. Sci., 2003, 75(1), 25-30.
55. Rozio, M.; Fracasso, C.; Riva, A.; Morazzoni, P.; Caccia, S. High-performance liquid chromatography measurement of hyperforin and its reduced derivatives in rodent plasma. J. Chromatogr. B Analyt. Techno.l Biomed. Life Sci., 2005, 816(1-2), 21-27.
56. Butterweck, V.; Jurgenliemk, G.; Nahrstedt, A.; Winterhoff, H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med., 2000, 66(1), 3-6.
57. Noldner, M.; Schotz, K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med., 2002, 68(7), 577-580.
58. Paulke, A.; Noldner, M.; Schubert-Zsilavecz, M.; Wurglics, M. St. John's wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral doses. Pharmazie, 2008, 63(4), 296-302.
59. Ioannides, C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica, 2002, 32(6), 451-478.
60. Pal, D.; Mitra, A.K. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci., 2006, 78(18), 2131-2145.
61. Wurglics, M.; Schubert-Zsilavecz, M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin. Pharmacokinet., 2006, 45(5), 449-468.
62. Juergenliemk, G.; Boje, K.; Huewel, S.; Lohmann, C.; Galla, H.J.; Nahrstedt, A. In vitro studies indicate that miquelianin (quercetin 3-O-beta-D-glucuronopyranoside) is able to reach the CNS from the small intestine. Planta Med., 2003, 69(11), 1013-1017.
63. Mullen, W.; Graf, B.A.; Caldwell, S.T.; Hartley, R.C.; Duthie, G.G.; Edwards, C.A.; Lean, M.E.; Crozier, A. Determination of flavonol metabolites in plasma and tissues of rats by HPLC-radiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4'-glucoside. J. Agric. Food Chem., 2002, 50(23), 6902-6909.
64. Fricker, G. Drug interactions with natural products at the blood brain barrier. Curr. Drug Metab., 2008, 9(10), 1019-1026.
65. Youdim, K.A.; Shukitt-Hale, B.; Joseph, J.A. Flavonoids and the brain: interactions at the blood-brain barrier and their physiological effects on the central nervous system. Free Radic. Biol. Med., 2004, 37(11), 1683-1693.
66. de Boer, V.C.; Dihal, A.A.; van der Woude, H.; Arts, I.C.; Wolffram, S.; Alink, G.M.; Rietjens, I.M.; Keijer, J.; Hollman, P.C. Tissue distribution of quercetin in rats and pigs. J. Nutr., 2005, 135(7), 1718-1725.
67. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung, 2005, 55(1), 15-22.
68. Ohnishi, R.; Ito, H.; Iguchi, A.; Shinomiya, K.; Kamei, C.; Hatano, T.; Yoshida, T. Effects of chlorogenic acid and its metabolites on spontaneous locomotor activity in mice. Biosci. Biotechnol. Biochem., 2006, 70(10), 2560-2563.
69. Shinomiya, K.; Omichi, J.; Ohnishi, R.; Ito, H.; Yoshida, T.; Kamei, C. Effects of chlorogenic acid and its metabolites on the sleep-wakefulness cycle in rats. Eur. J. Pharmacol., 2004, 504(3), 185-189.
70. Takeda, H.; Tsuji, M.; Inazu, M.; Egashira, T.; Matsumiya, T. Rosmarinic acid and caffeic acid produce antidepressive-like effect in the forced swimming test in mice. Eur. J. Pharmacol., 2002, 449(3), 261-267.
71. Takeda, H.; Tsuji, M.; Miyamoto, J.; Masuya, J.; Iimori, M.; Matsumiya, T. Caffeic acid produces antidepressive- and/or anxiolytic-like effects through indirect modulation of the alpha 1A-adrenoceptor system in mice. Neuroreport, 2003, 14(7), 1067-1070.
72. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 2005, 81(1 Suppl), 230S-242S.
73. Yang, C.S.; Sang, S.; Lambert, J.D.; Lee, M.J. Bioavailability issues in studying the health effects of plant polyphenolic compounds. Mol. Nutr. Food Res., 2008, 52 (Suppl 1), S139-151.
74. Holt, R.R.; Lazarus, S.A.; Sullards, M.C.; Zhu, Q.Y.; Schramm, D.D.; Hammerstone, J.F.; Fraga, C.G.; Schmitz, H.H.; Keen, C.L. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am. J. Clin. Nutr., 2002, 76(4), 798-804.
75. Patočka, J. The chemistry, pharmacology, and toxicology of the biologically active constituents of the herb Hypericum perforatum L. J. Appl. Biomed., 2003, 1, 61-70.
76. Butterweck, V.; Nahrstedt, A. What is known about St. John's wort? Phytochemistry and pharmacology. Pharm. Unserer Zeit., 2003, 32(3), 212-219.
77. Zanoli, P. Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev., 2004, 10(3), 203-218.
78. Hammer, K.D.; Hillwig, M.L.; Solco, A.K.; Dixon, P.M.; Delate, K.; Murphy, P.A.; Wurtele, E.S.; Birt, D.F. Inhibition of prostaglandin E(2) production by anti-inflammatory hypericum perforatum extracts and constituents in RAW264.7 Mouse Macrophage Cells. J. Agric. Food Chem., 2007, 55(18), 7323-7331.
79. Ma, S.C.; But, P.P.; Ooi, V.E.; He, Y.H.; Lee, S.H.; Lee, S.F.; Lin, R.C. Antiviral amentoflavone from Selaginella sinensis. Biol. Pharm. Bull., 2001, 24(3), 311-312.
80. Kang, S.S.; Lee, J.Y.; Choi, Y.K.; Song, S.S.; Kim, J.S.; Jeon, S.J.; Han, Y.N.; Son, K.H.; Han, B.H. Neuroprotective effects of naturally occurring biflavonoids. Bioorg. Med. Chem. Lett., 2005, 15(15), 3588-3591.
81. Shin, D.H.; Bae, Y.C.; Kim-Han, J.S.; Lee, J.H.; Choi, I.Y.; Son, K.H.; Kang, S.S.; Kim, W.K.; Han, B.H. Polyphenol amentoflavone affords neuroprotection against neonatal hypoxic-ischemic brain damage via multiple mechanisms. J. Neurochem., 2006, 96(2), 561-572.
82. Lee, H.S.; Oh, W.K.; Kim, B.Y.; Ahn, S.C.; Kang, D.O.; Shin, D.I.; Kim, J.; Mheen, T.I.; Ahn, J.S. Inhibition of phospholipase C gamma 1 activity by amentoflavone isolated from Selaginella tamariscina. Planta Med., 1996, 62(4), 293-296.
83. Bucar, F.; Jachak, S.M.; Noreem, Y.; Kartnig, T.; Perera, P.; Bohlin, L.; Schubert-Zsilavecz, M. Amentoflavone from Biophytum sensitivum and its effect on COX-1/COX-2 catalysed prostaglandin biosynthesis. Planta Med., 1998, 64(4), 373-374.
84. Saponara, R.; Bosisio, E. Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. J. Nat. Prod., 1998, 61(11), 1386-1387.
85. Woo, E.R.; Lee, J.Y.; Cho, I.J.; Kim, S.G.; Kang, K.W. Amentoflavone inhibits the induction of nitric oxide synthase by inhibiting NF-kappaB activation in macrophages. Pharmacol. Res., 2005, 51(6), 539-546.
86. Pan, X.; Tan, N.; Zeng, G.; Zhang, Y.; Jia, R. Amentoflavone and its derivatives as novel natural inhibitors of human Cathepsin B. Bioorg. Med. Chem., 2005, 13(20), 5819-5825.
87. Gutmann, H.; Bruggisser, R.; Schaffner, W.; Bogman, K.; Botomino, A.; Drewe, J. Transport of amentoflavone across the blood-brain barrier in vitro. Planta Med., 2002, 68(9), 804-807.
88. Nielsen, M.; Frokjaer, S.; Braestrup, C. High affinity of the naturally-occurring biflavonoid, amentoflavon, to brain benzodiazepine receptors in vitro. Biochem. Pharmacol., 1988, 37(17), 3285-3287.
89. Colovic, M.; Fracasso, C.; Caccia, S. Brain-to-plasma distribution ratio of the biflavone amentoflavone in the mouse. Drug Metab. Lett., 2008, 2(2), 90-94.
90. Colovic, M.; Caccia, S. Liquid chromatography-tandem mass spectrometry of I3,II8-biapigenin, the major biflavone in Hypericum perforatum extracts. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 863(1), 74-79.
91. Miskovsky, P. Hypericin--a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr. Drug Targets, 2002, 3(1), 55-84.
92. Kubin, A.; Wierrani, F.; Burner, U.; Alth, G.; Grunberger, W. Hypericin - the facts about a controversial agent. Curr. Pharm. Des., 2005, 11(2), 233-253.
93. Butterweck, V.; Korte, B.; Winterhoff, H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry, 2001, 34 (Suppl 1), S2-7.
94. Kerb, R.; Brockmoller, J.; Staffeldt, B.; Ploch, M.; Roots, I. Singledose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob. Agents Chemother., 1996, 40(9), 2087-2093.
95. Brockmoller, J.; Reum, T; Bauer, S; Kerb, R; Hübner, WD; Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry, 1997, 30 (Suppl 2): 94-101.
96. 14C]-labeled hypericin an pseudohypericin from Hypericum perforatum and serum kinetics of hypericin in man. Planta Med., 1991, 57 (Suppl 2), A61.
97. Fox, E.; Murphy, R.F.; McCully, C.L.; Adamson, P.C. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother. Pharmacol., 2001, 47(1), 41-44.
98. Butterweck, V.; Nahrstedt, A.; Evans, J.; Hufeisen, S.; Rauser, L.; Savage, J.; Popadak, B.; Ernsberger, P.; Roth, B.L. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology (Berl), 2002, 162(2), 193-202.
99. Muller, W.E.; Rolli, M.; Schafer, C.; Hafner, U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry, 1997, 30 (Suppl 2),102-107.
100. Muller, W.E.; Singer, A.; Wonnemann, M.; Hafner, U.; Rolli, M.; Schafer, C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 1998, 31 (Suppl 1),16-21.
101. Gobbi, M.; Dalla Valle, F.; Ciapparelli, C.; Diomede, L.; Morazzoni, P.; Verotta, L.; Caccia, S.; Cervo, L.; Mennini, T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn. Schmiedebergs Arch. Pharmacol., 1999, 360(3), 262-269.
102. Di Carlo, G.; Borrelli, F.; Ernst, E.; Izzo, A.A. St John's wort: Prozac from the plant kingdom. Trends Pharmacol. Sci., 2001, 22(6), 292-297.
103. Singer, A.; Wonnemann, M.; Muller, W.E. J. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. Pharmacol. Exp. Ther., 1999, 290(3), 1363-1368.
104. Gobbi, M.; Moia, M.; Pirona, L.; Morazzoni, P.; Mennini, T. In vitro binding studies with two hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry, 2001, 34 (Suppl 1), S45-48.
105. Roz, N.; Mazur, Y.; Hirshfeld, A.; Rehavi, M. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci., 2002, 71(19), 2227-2237.
106. Treiber, K.; Singer, A.; Henke, B.; Müller, W.E. Hyperforin activates nonselective cation channels (NSCCs). Br. J. Pharmacol., 2005, 145(1), 75-83.
107. Roz, N.; Rehavi, M. Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci., 2003, 73(4), 461-470.
108. Chatterjee, S.S.; Biber, A.; Weibezahn, C. Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin. Pharmacopsychiatry, 2001, 34 (Suppl 1), S11-19.
109. Gobbi, M.; Mennini, T. In St. Johǹs Wort and its active principles in depression and anxiety, W. E. Muller, Ed.; Birkhäuser Verlag, Basel; Boston - Berlin, 2004, pp. 21-29.
110. Panocka, I.; Perfumi, M.; Angeletti, S.; Ciccocioppo, R.; Massi, M. Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved. Pharmacol. Biochem. Behav., 2000, 66(1), 105-111.
111. Matsuno, K.; Kobayashi, T.; Tanaka, M.K.; Mita, S. Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur. J. Pharmacol., 1996, 312(3), 267-271.
112. Dantzer, R.; Wollman, E.E.; Yirmiya, R. Cytokines and depression: an update. Brain Behav. Immun., 2002,16(5),501-2.
113. Besedovsky, H.O.; del Rey, A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr. Rev., 1996, 17(1), 64-102.
114. Calapai, G.; Crupi, A.; Firenzuoli, F.; Inferrera, G.; Ciliberto, G.; Parisi, A.; De Sarro, G.; Caputi, A.P. Interleukin-6 involvement in antidepressant action of Hypericum perforatum. Pharmacopsychiatry, 2001, 34 (Suppl 1), S8-10.
115. Fiebich, B.L.; Hollig, A.; Lieb, K. Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry, 2001, 34 (Suppl 1), S26-28.
116. Thiele, B.; Brink, I.; Ploch, M. Modulation of Cytokine Expression by Hypericum Extract . J. Geriatr. Psychiatry Neurol., 1994, 7 (Suppl 1), S60-62.
117. Gobbi, M.; Moia, M.; Funicello, M.; Riva, A.; Morazzoni, P.; Mennini, T. In vitro effects of the dicyclohexylammonium salt of hyperforin on interleukin-6 release in different experimental models. Planta Med., 2004, 70, 680-682.
118. Calapai, G.; Crupi, A.; Firenzuoli, F.; Inferrera, G.; Squadrito, F.; Parisi, A.; De Sarro, G.; Caputi, A. Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum. Pharmacopsychiatry, 2001, 34(2), 45-49.
119. Butterweck, V.; Wall, A.; Lieflander-Wulf, U.; Winterhoff, H.; Nahrstedt, A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry, 1997, 30 (Suppl 2),117-124.
120. Butterweck, V.; Petereit, F.; Winterhoff, H.; Nahrstedt, A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med., 1998, 64(4), 291-294.
121. Calapai, G.; Crupi, A.; Firenzuoli, F.; Costantino, G.; Inferrera, G.; Campo, G.M.; Caputi, A.P. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat. J. Pharm. Pharmacol., 1999, 51(6), 723-728.
122. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. Effect of acute administration of hypericum perforatum-CO2 extract on dopamine and serotonin release in the rat central nervous system. Pharmacopsychiatry, 2000, 33(1), 14-18.
123. Baureithel, K.H.; Buter, K.B.; Engesser, A.; Burkard, W.; Schaffner, W. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm. Acta Helv., 1997, 72(3), 153-157.
124. Gobbi, M.; Mennini, T. Is St John's wort a 'Prozac-like' herbal antidepressant? Trends Pharmacol. Sci., 2001, 22(11), 557-559.
125. Haass, C.; Selkoe, D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8(2), 101-112.
126. Campiani, G.; Butini, S.; Trotta, F.; Fattorusso, C.; Catalanotti, B.; Aiello, F.; Gemma, S.; Nacci, V.; Novellino, E.; Stark, J.A.; Cagnotto, A.; Fumagalli, E.; Carnovali, F.; Cervo, L.; Mennini, T. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J. Med. Chem., 2003, 46(18), 3822-3839.
127. Hall, S.D.; Wang, Z.; Huang, S.M.; Hamman, M.A.; Vasavada, N.; Adigun, A.Q.; Hilligoss, J.K.; Miller, M.; Gorski, J.C. The interaction between St John's wort and an oral contraceptive. Clin. Pharmacol. Ther., 2003, 74(6), 525-535.
128. Johne, A.; Brockmoller, J.; Bauer, S.; Maurer, A.; Langheinrich, M.; Roots, I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther., 1999, 66(4), 338-345.
129. Paulke, A.; Schubert-Zsilavecz, M.; Wurglics, M. Determination of St. John's wort flavonoid-metabolites in rat brain through high performance liquid chromatography coupled with fluorescence detection. J. Chromatogr. B Analy.t Technol. Biomed. Life Sci., 2006, 832(1), 109-113.